论文部分内容阅读
目的评价力克肺疾与莫西沙星联合方案对耐多药肺结核(MDR-TB)的疗效。方法100例MDR-TB患者随机分为两组,每组50例。治疗组用莫西沙星0.4 g/d,力克肺疾1.0 g/d。对照组用左氧氟沙星0.4 g/d,丁胺卡那霉素0.6 g/d,疗程12个月,同时辅以其他抗结核药。结果第3个月末,治疗组痰菌转阴率为74%,明显优于对照组的43%,两组比较差异有统计学意义(P<0.05)。疗程结束时,治疗组痰菌转阴率为96%,明显优于对照组的70%,两组比较差异有统计学意义(P<0.05)。结论以力克肺疾与莫西沙星联合其他抗结核药物组成的化疗方案对MDR-TB疗效肯定,痰菌转阴速度快,值得继续临床探索。
Objective To evaluate the efficacy of combination of Lectra Pulmonary Disease and Moxifloxacin against multidrug-resistant pulmonary tuberculosis (MDR-TB). Methods 100 cases of MDR-TB patients were randomly divided into two groups, 50 cases in each group. The treatment group with moxifloxacin 0.4 g / d, Lectra pulmonary disease 1.0 g / d. Control group levofloxacin 0.4 g / d, amikacin 0.6 g / d, treatment for 12 months, supplemented by other anti-TB drugs. Results At the end of the third month, the sputum negative rate of the treatment group was 74%, which was significantly better than that of the control group (43%). There was significant difference between the two groups (P <0.05). At the end of treatment, the rate of sputum negative conversion in the treatment group was 96%, which was significantly better than that in the control group (70%). There was significant difference between the two groups (P <0.05). Conclusion The chemotherapy regimen composed of Lectra Pulmonary Disease and moxifloxacin in combination with other anti-TB drugs affirmed the efficacy of MDR-TB, and the sputum negative conversion rate is fast, so it is worth further clinical exploration.